A nested case-control study of over 7000 patients in Taiwan found that individuals who had taken a DPP4 inhibitor in the last 365 days were more likely to develop acute kidney injury (OR = 1.2; 95% CI 1.11–1.37)10. The gene discussed is DPP4; the disease is acute kidney injury.